Chemo with or without immunotherapy for peritoneal mesothelioma
Treatments studied
Part of Cancer clinical trials.
This study tests whether adding immunotherapy to standard chemotherapy helps people with peritoneal mesothelioma, a cancer in the lining of the abdomen. You may receive chemotherapy alone or with immunotherapy, and the goal is to improve cancer control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed malignant peritoneal mesothelioma and have not had any prior treatment for it
- Your cancer can be measured on scans (doctors can track its size or spread)
- You must be able to consent and have good enough strength for treatment (ECOG 0–1)
- Your blood counts and organ tests must be high enough (white cells, neutrophils, platelets, kidney and liver tests)
- You must not be pregnant or breastfeeding, and if you can get pregnant, you must use reliable birth control
- You cannot have certain other serious illnesses (like uncontrolled infection or major heart disease) or active autoimmune/immune problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs (sintilimab, bevacizumab, pemetrexed, and cisplatin) to see if they can shrink or control peritoneal mesothelioma that cannot be surgically removed. It may be an option if you have this rare cancer and are in fairly good health.
This trial tests whether more chemotherapy after surgery can help people with a specific type of abdominal cancer (malignant peritoneal mesothelioma). It is for those who have had all visible tumor removed and have not had chemotherapy before.
This trial studies how well pembrolizumab (an immune therapy) works when added to chemotherapy before image-guided surgery for malignant pleural mesothelioma. It aims to shrink or control the cancer and improve surgical results by combining treatments.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with chemotherapy for people with malignant mesothelioma that cannot be treated with surgery or radiation. It may be an option whether you are starting treatment for the first time or have had up to three prior treatments.
This trial uses a test on your tumor tissue to find which chemotherapy drugs work best for you, after standard surgery and heated chemotherapy. It aims to make your treatment more effective by choosing drugs that match your cancer.
This trial tests whether adding cadonilimab (an immune treatment) and bevacizumab (a medicine that targets blood supply to tumors) to standard chemotherapy can control pleural malignant mesothelioma that cannot be removed with surgery. It’s meant for people who have not yet started medicine for advanced disease and who meet health and blood test requirements.
Hear when a new Peritoneal Malignant Mesothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.